Details for Patent: 10,376,470

Which drugs does patent 10,376,470 protect, and when does it expire?

Patent 10,376,470 protects ROSZET and is included in one NDA.

This patent has eleven patent family members in ten countries.

Summary for Patent: 10,376,470

Title:	Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
Abstract:	Solid dosage formulations containing a combination of rosuvastatin and ezetimibe, as well as methods of making such solid dosage forms and method of treating patients with fixed combination solid dosage forms of rosuvastatin and ezetimibe are provided here.
Inventor(s):	Dias; Marie Charmaine (Morristown, NJ), Ramani; Chandir (Brapton, CA)
Assignee:	Althera Life Sciences, LLC (Morristown, NJ)
Application Number:	15/687,492
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 10,376,470

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Althera Pharms	ROSZET	ezetimibe; rosuvastatin calcium	TABLET;ORAL	213072-001	Mar 23, 2021		DISCN	Yes	No			Y			TREATMENT OF HYPERLIPIDEMIA
Althera Pharms	ROSZET	ezetimibe; rosuvastatin calcium	TABLET;ORAL	213072-002	Mar 23, 2021		DISCN	Yes	No			Y			TREATMENT OF HYPERLIPIDEMIA
Althera Pharms	ROSZET	ezetimibe; rosuvastatin calcium	TABLET;ORAL	213072-003	Mar 23, 2021		DISCN	Yes	No			Y			TREATMENT OF HYPERLIPIDEMIA
Althera Pharms	ROSZET	ezetimibe; rosuvastatin calcium	TABLET;ORAL	213072-004	Mar 23, 2021		DISCN	Yes	No			Y			TREATMENT OF HYPERLIPIDEMIA

International Family Members for US Patent 10,376,470

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Cyprus	1123091
Denmark	2844233
European Patent Office	2844233
Spain	2802252